Skip to main content
. 2012 Jun;7(6):926–933. doi: 10.2215/CJN.09930911

Figure 3.

Figure 3.

Renal and patient outcome in patients with and without antibodies against P16 and P22, respectively. Kaplan–Meier analysis for renal (A) and patient (B) survival compared between patients with and without antibodies against P16 and P22, respectively. HR, hazard ratio; 95% CI, 95% confidence interval.